F. Hoffmann-La Roche Ltd e altri: le informazioni ingannevoli possono nuocere alla salute... e alla concorrenza

Abstract

(Series Information) European Papers - A Journal on Law and Integration, 2018 3(2), 1005-1016 | European Forum Insight of 13 June 2018 | (Table of Contents) I. Introduzione. - II. Il caso. - III. Le conclusioni dell'AG Saugmandsgaard Øe. - IV. La sentenza della Corte di giustizia. - V. Le informazioni ingannevoli nel diritto dell'Unione e quale problema rilevante per il diritto della concorrenza. - VI. Conclusioni. | (Abstract) In a recent case (judgment of 23 January 2018, case C-179/16, Hoffmann-La Roche and others), the Court of Justice held that an arrangement put in place between two undertakings marketing two competing products, which concerned the dissemination of misleading information relating to adverse reactions resulting from the use of one of those medicinal products, with a view to reducing competitive pressure, constituted a restriction of competition "by object" for the purposes of Art. 101, para. 1, TFEU. The purpose of this Insight is to provide an analysis of the case, focusing on both the opinion of the Advocate General and the judgment, and to provide further examples that prove that the dissemination of misleading information in the pharmaceutical field has become a competition law problem.

Keywords

• competition law
• misleading information
• medicinal products
• side effects
• cjeu
• restriction of competition by object